Modular robotic surgery to remove GEJ cancers at Siewert II/III

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses a split-type, modular robotic surgical system to perform robotic-assisted radical resection for Siewert type II/III gastroesophageal junction cancer. Eligible patients are adults with confirmed tumors at the GEJ suitable for curative surgery and good organ function. The trial aims to assess short-term safety and perioperative outcomes of this approach across abdominal and mediastinal work zones. Participants will undergo robotic-assisted resection with planned lymph node dissection, and perioperative data will be collected to describe feasibility and immediate postoperative results. The study is conducted at a single center, led by The First Hospital of Jilin University, and does not specify a randomized comparator.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 80 years, inclusive, regardless of sex.
2. Histologically and/or cytologically confirmed Siewert type II or type III gastroesophageal junction tumor, with clinical staging according to AJCC 8th edition TNM classification indicating suitability for curative surgical resection.
3. Adequate organ function as assessed by the investigator before surgery.
4. Provision of written informed consent and willingness to participate in the study.
5. Ability and willingness to comply with study procedures and follow-up requirements.
6. ECOG performance status of 0-1.
7. Absence of distant metastasis confirmed by preoperative thoracoabdominal and pelvic CT or PET-CT.

Exclusion Criteria:

1. Patients with body mass index (BMI) \<18.5 kg/m² or BMI ≥35 kg/m².
2. Patients with severe cardiac, pulmonary, neurological, hepatic, or renal diseases that may prevent tolerance of surgery or anesthesia.
3. Patients unable to tolerate pneumoperitoneum or considered by the investigator to have extensive intra-abdominal adhesions or other conditions preventing safe establishment of pneumoperitoneum.
4. Patients with severe coagulation disorders that contraindicate minimally invasive surgery.
5. Patients with active pulmonary tuberculosis.
6. Patients with severe uncontrolled diseases, acute infections, severe physical deterioration, massive ascites, active intra-abdominal bleeding, or shock.
7. Patients with metastatic lymph nodes fused together or encasing major blood vessels, making curative resection infeasible.
8. Patients with previous abdominal/pelvic surgery, radiotherapy, or chemotherapy that may affect the feasibility of laparoscopic or robotic surgery.
9. Pregnant or breastfeeding women.
10. Patients currently participating in other clinical trials involving investigational drugs or medical devices.
11. Patients considered unsuitable for this study by the investigator.

Where it's running

• First Hospital of Jilin Universiry
  Changchun, Jilin, China Recruiting

Study contacts

• Study coordinator: Quan Wang
• Email: wquan@jlu.edu.cn
• Phone: +86 15843073207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retroperitoneal Tumor Registry

  This observational registry collects real-world data from people with retroperitoneal tumors to help understand features, treatments, and long-term outcomes.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07915895

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Vision-language AI helps emergency CT readers spot thoraco-abdominal problems

  This trial tests whether a self-developed AI model can help radiologists find acute thoraco-abdominal emergencies on CT scans more accurately than standard reading in adult emergency patients.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07899931

• Tegileridine for pain after bariatric surgery

  This phase 3 trial tests tegileridine vs standard opioid medicine to see if it provides good pain relief after bariatric surgery while considering sleep apnea status.

  Recruiting Phase 3 The First Hospital of Jilin University · Changchun, Jilin · NCT07844512

• Removing enlarged cardiophrenic lymph nodes during surgery for advanced ovarian cancer

  This will try removing enlarged cardiophrenic lymph nodes during surgery in women with advanced ovarian, fallopian tube, or primary peritoneal cancer to see if it delays cancer coming back and is safe.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07572409

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.